Interleukin-1 inhibitors for acute gout-Reference-Cited by-同舟云学术

Interleukin-1 inhibitors for acute gout

Published:2014-09-01 Issue: Volume: Page:
ISSN:1465-1858
Container-title:Cochrane Database of Systematic Reviews
language:en
Short-container-title:

Author:

Sivera Francisca¹,Wechalekar Mihir D²,Andrés Mariano³,Buchbinder Rachelle⁴,Carmona Loreto⁵

Affiliation:

1. Hospital de Elda; Servicio de Reumatologia; Ctra. Elda-Sax, PTDA. La Torreta, S/N Elda (Alicante) Spain 03600

2. Repatriation General Hospital; Rheumatology Unit; Daws Road Daw Park South Australia Australia 5041

3. Hospital General Universitario de Alicante; Sección de Reumatología; C/ Pintor Baeza, 12 Alicante Spain 03010

4. Department of Epidemiology and Preventive Medicine, School of Public Health and Preventive Medicine, Monash University; Monash Department of Clinical Epidemiology, Cabrini Hospital; Suite 41, Cabrini Medical Centre 183 Wattletree Road Malvern Victoria Australia 3144

5. Instituto de Salud Musculoesquelética; Calle Ofelia Nieto, 10 Madrid Spain 28039

Publisher

Wiley

Subject

Pharmacology (medical)

Reference42 articles.

1. NCT01029652 Canakinumab in the treatment of acute gout flares and prevention of new flares in patients unable to use non-steroidal anti-inflammatory drugs (NSAIDs) and/or colchicine including a 12 weeks extension and an open-label 48 weeks extension study (β-RELIEVED) clinicaltrials.gov/show/NCT01029652

2. Canakinumab for acute gouty arthritis in patients with limited treatment options: results from two randomised, multicentre, active-controlled, double-blind trials and their initial extensions;Schlesinger;Annals of the Rheumatic Diseases,2012

3. NCT01080131 Canakinumab in the treatment of acute gout flares and prevention of new flares in patients unable to use non-steroidal anti-inflammatory drugs (NSAIDs) and/or colchicines including a 12 week extension and a 1 year open-label extension study (β-RELIEVED-II) clinicaltrials.gov/show/NCT01080131

4. Canakinumab for acute gouty arthritis in patients with limited treatment options: results from two randomised, multicentre, active-controlled, double-blind trials and their initial extensions;Schlesinger;Annals of the Rheumatic Diseases,2012

5. NCT00798369 Targeted dose finding of canakinumab (ACZ885) for management of acute flare in refractory or contraindicated gout patients clinicaltrials.gov/show/NCT00798369

Cited by 23 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Triterpenes Drug Delivery Systems, a Modern Approach for Arthritis Targeted Therapy;Pharmaceuticals;2023-12-28

2. Haloperidol inhibits inflammasome activation via LAMTOR1 and reduces the risk of arthritides;2023-12-08

3. Interleukin-1β inhibitors for the management of acute gout flares: a systematic literature review;Arthritis Research & Therapy;2023-07-25

4. Efficacy and Safety of Qinpi Tongfeng Formula Combined with Bloodletting Therapy in the Treatment of Acute Gouty Arthritis: A Study Protocol for a Randomized Controlled Trial;Evidence-Based Complementary and Alternative Medicine;2022-01-21

5. 2021 Asia‐Pacific League of Associations for Rheumatology clinical practice guideline for treatment of gout;International Journal of Rheumatic Diseases;2021-12-20